Oral Anticoagulation
10
3
4
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
Stroke of Unknown Cause in Women: The Impact of Long-term Heart Monitoring on Stroke Recurrence
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime
Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
Atrial Fibrillation After CABG and PCI
User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid
Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting